Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221036265> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W4221036265 endingPage "10" @default.
- W4221036265 startingPage "P4" @default.
- W4221036265 abstract "Abstract There is a general consensus that the devastating effect of malignant breast cancers (MBCs) is due in part to the ability of breast tumors to exploit host immune functions by subverting normal mechanisms of immunosurveillance. For example, while immunotherapies based on immune checkpoint inhibition in lymphocytes have been associated with better prognosis in other cancers, the efficacy in breast cancer has been limited. We focus here on activating biochemical pathways in antigen-presenting dendritic cells (DCs) that are otherwise immunosuppressive to stimulate the activity of tumor-infiltrating lymphocytes through a novel mechanism. To this end, we recently discovered using an immune-competent mouse model of MBC that breast cancer cells exploit adaptive immune cells such as DCs that express CHRNA7, the α7 nicotinic acetylcholine receptor. Based on the importance of the CHRNA7 signaling pathway in the control of normal inflammation in macrophages in general, we show here that CHRNA7 stimulation in DCs leads to an activation of lymphocytes associated with a reduction in MBC. Specifically, mice lacking the CHRNA7 gene have (a) decreased survival, (b) increased tumor growth kinetics, (c) immunophenotyping revealed a reduction in the “cancer-permissive” phenotype in CHRNA7 KO mice, and (d), a commensurate reduction in T cell proliferation. Based on these mechanistic proof of principle studies, we demonstrate that in contrast to the loss of CHRNA7 in KO, pharmacological activation of CHRNA7 with AR-R17779 has the opposite effect by stimulating DCs to activate the adaptive immune response which leads to tumor progression and increased survival. These findings demonstrate the preclinical potential of AR-R17779 as a clinically relevant approach to stimulate the adaptive immune system through a novel pathway that has not been examined to date, and with a small molecule drug that is stable, specific and well-tolerated. Citation Format: Brian P. Eliceiri, Jin Qian, Sarah Blair. Pharmacological targeting of cholinergic receptors as a novel breast cancer immunotherapy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-04-10." @default.
- W4221036265 created "2022-04-03" @default.
- W4221036265 creator A5024786945 @default.
- W4221036265 creator A5048704005 @default.
- W4221036265 creator A5056827682 @default.
- W4221036265 date "2022-02-15" @default.
- W4221036265 modified "2023-10-11" @default.
- W4221036265 title "Abstract P4-04-10: Pharmacological targeting of cholinergic receptors as a novel breast cancer immunotherapy" @default.
- W4221036265 doi "https://doi.org/10.1158/1538-7445.sabcs21-p4-04-10" @default.
- W4221036265 hasPublicationYear "2022" @default.
- W4221036265 type Work @default.
- W4221036265 citedByCount "0" @default.
- W4221036265 crossrefType "journal-article" @default.
- W4221036265 hasAuthorship W4221036265A5024786945 @default.
- W4221036265 hasAuthorship W4221036265A5048704005 @default.
- W4221036265 hasAuthorship W4221036265A5056827682 @default.
- W4221036265 hasConcept C121608353 @default.
- W4221036265 hasConcept C193419808 @default.
- W4221036265 hasConcept C203014093 @default.
- W4221036265 hasConcept C2776885095 @default.
- W4221036265 hasConcept C2777701055 @default.
- W4221036265 hasConcept C2780674031 @default.
- W4221036265 hasConcept C502942594 @default.
- W4221036265 hasConcept C530470458 @default.
- W4221036265 hasConcept C54355233 @default.
- W4221036265 hasConcept C86803240 @default.
- W4221036265 hasConcept C8891405 @default.
- W4221036265 hasConceptScore W4221036265C121608353 @default.
- W4221036265 hasConceptScore W4221036265C193419808 @default.
- W4221036265 hasConceptScore W4221036265C203014093 @default.
- W4221036265 hasConceptScore W4221036265C2776885095 @default.
- W4221036265 hasConceptScore W4221036265C2777701055 @default.
- W4221036265 hasConceptScore W4221036265C2780674031 @default.
- W4221036265 hasConceptScore W4221036265C502942594 @default.
- W4221036265 hasConceptScore W4221036265C530470458 @default.
- W4221036265 hasConceptScore W4221036265C54355233 @default.
- W4221036265 hasConceptScore W4221036265C86803240 @default.
- W4221036265 hasConceptScore W4221036265C8891405 @default.
- W4221036265 hasIssue "4_Supplement" @default.
- W4221036265 hasLocation W42210362651 @default.
- W4221036265 hasOpenAccess W4221036265 @default.
- W4221036265 hasPrimaryLocation W42210362651 @default.
- W4221036265 hasRelatedWork W2783288907 @default.
- W4221036265 hasRelatedWork W2893846263 @default.
- W4221036265 hasRelatedWork W2965482317 @default.
- W4221036265 hasRelatedWork W3015997773 @default.
- W4221036265 hasRelatedWork W3049036915 @default.
- W4221036265 hasRelatedWork W3111580887 @default.
- W4221036265 hasRelatedWork W3154696046 @default.
- W4221036265 hasRelatedWork W3185708072 @default.
- W4221036265 hasRelatedWork W4244021869 @default.
- W4221036265 hasRelatedWork W4289540427 @default.
- W4221036265 hasVolume "82" @default.
- W4221036265 isParatext "false" @default.
- W4221036265 isRetracted "false" @default.
- W4221036265 workType "article" @default.